Stocktoria
60 DEGREES PHARMACEUTICALS, INC. SXTP
60 DEGREES PHARMACEUTICALS, INC. (SXTP) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $1.0M at a -732.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.43 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | 3/9 | — | — | — |
| STTK | Shattuck Labs, Inc. | 3/9 | -3.77 | — | — |
| DARE | Dare Bioscience, Inc. | 3/9 | — | — | — |
| RFL | Rafael Holdings, Inc. | 3/9 | 0.8 | — | — |
| RNXT | RenovoRx, Inc. | 2/9 | — | — | — |
| SXTC | China SXT Pharmaceuticals, Inc. | 3/9 | 2.19 | — | — |
| RLYB | Rallybio Corp | 3/9 | 0.76 | — | — |
About 60 DEGREES PHARMACEUTICALS, INC.
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.
FAQ
Is SXTP financially healthy?
60 DEGREES PHARMACEUTICALS, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does SXTP pay a dividend?
No, 60 DEGREES PHARMACEUTICALS, INC. does not currently pay a dividend.
How profitable is SXTP?
In FY2025, 60 DEGREES PHARMACEUTICALS, INC. had a net margin of -732.5% and a return on equity of -212.7%.
What is the analyst price target for SXTP?
The average Wall-Street price target for 60 DEGREES PHARMACEUTICALS, INC. is $3.70, about 227.4% above the recent price, from 1 analysts.
Is SXTP a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on 60 DEGREES PHARMACEUTICALS, INC.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.